TickerTalks
Browse all tickers →
TickerTalks›$EWTX
EWEWTX

Edgewise Therapeutics, Inc.

$EWTX·$4.0B·Biotechnology·Healthcare
$36.81+5.7%YTD+46.8%1Y+154.4%
Mentions · last 7 days
0
Price updated 32m ago
EWEWTX
Edgewise Therapeutics, Inc.$EWTX
$36.81+5.72%0 posts
AI analysisFundamentalsVoices on X
Loading…

What it does

Plain-English summary of the business — what they sell and how they make money.

Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $EWTX.

Biotechnology · Healthcare

GLP-1 obesity pipeline competition is the dominant structural driver — the 'next phase' of obesity drugs (oral formulations, differentiated mechanisms) is reshaping clinical bets for NVO competitors. Gene editing (CRSP, BEAM, NTLA, PRME) is transitioning from clinical to commercial-maturation phase with Casgevy scaling; oncology binary events (IBRX, ALLO, KURA) define the near-term calendar.

Top industry ETF

$IBBiShares Biotechnology ETF
+2.4%YTD
+38.1%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-22.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-40.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-3.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-32.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-0.46$-0.50+8.0%
Q4 2025Feb 26, 2026$-0.47$-0.43-9.3%
Q3 2025Nov 6, 2025$-0.39$-0.40+2.5%
Q2 2025Aug 7, 2025$-0.34$-0.42+19.0%
Next earningsThu, Aug 6·consensus EPS $-0.50

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.46$-42.8M
Q4 FY25$0———$-0.47$-38.4M
Q3 FY25$0———$-0.39$-34.9M
Q2 FY25$0———$-0.34$-32.6M

Forward consensus

5-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$2.3M$647K – $4.8M-$1.95-$2.23 – -$1.735
FY27$37.5M$2.4M – $92.8M-$1.77-$2.66 – -$0.375
FY28$82.9M$23.6M – $176.5M-$1.65-$1.79 – -$1.564
FY29$283.3M$80.7M – $603.0M$0.05$0.00 – $0.123
FY30$468.2M$133.3M – $996.6M$0.07$0.01 – $0.183

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.86%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+8.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+41.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 78.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellMay 5Joanne M. DonovanCMO50.0K sh$1.9MSellMay 4Joanne M. DonovanCMO5.2K sh$164KSellApr 1Joanne M. DonovanCMO28.7K sh$926KSellMar 31Joanne M. DonovanCMO21.3K sh$685KSellMar 27Joanne M. DonovanCMO16.4K sh$507KSellJan 21Badreddin EdrisDirector115.5K sh$3.4M
+ 12 other (8 awards · 4 exempts) in window

See when $EWTX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 58-K — Item 5.07: Shareholder vote
AI summary

Edgewise Therapeutics (EWTX) held its 2026 Annual Meeting on June 4, 2026 and filed an 8-K on June 5, 2026 reporting routine director election and proposal vote results (Item 5.07). No extraordinary governance changes were disclosed.

8-KMaterial agreementJun 18-K — Item 1.01: Material agreement
AI summary

Edgewise Therapeutics (EWTX) announced a major asset sale: on May 31, 2026, it signed an Asset Purchase Agreement with Servier Pharmaceuticals LLC and Les Laboratoires Servier to sell the sevasemten neuromuscular program for $1.55 billion in cash at closing (net of escrow amounts) plus a milestone payment contingent on US marketing approval. The transaction is subject to customary closing conditions. This is a transformative deal for Edgewise, monetizing a late-stage asset for over $1.5B in near-term cash, effectively a major partial liquidation of the company's pipeline value.

SC 13D/AActivist amendmentApr 27SC 13D/A
AI summary

Novo Holdings A/S (Denmark) filed Amendment No. 6 on a Schedule 13D for Edgewise Therapeutics (EWTX), disclosing current ownership of 5,350,000 shares representing approximately 4.9% of the class. The amendment was triggered not by a new purchase or sale but by dilution of Novo's position below the 5% 13D reporting threshold due to other share issuances. Novo remains a significant institutional holder of EWTX.

+ 10 other (2 13Gs · 2 earnings 8-Ks · 2 proxys · 1 S-8) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcriptseekingalpha.com·3d agoEdgewise Therapeutics Reports Improvements In Heart Drug Trialbenzinga.com·3d agoEdgewise shares slip after heart-disease drug trial data disappoints investorsreuters.com·3d agoEdgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)prnewswire.com·4d agoEdgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancementseekingalpha.com·15d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALLO$NVO$AURA$HUMA$ALT$IBRX$QURE$RXRX
Voices on X · top 4 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport